What are the recommended dosing, monitoring parameters, contraindications, and adverse effect counseling for enzalutamide in prostate cancer patients?

Enzalutamide Dosing and Management in Prostate Cancer

The standard dose of enzalutamide is 160 mg orally once daily, taken continuously without food restrictions or mandatory concurrent prednisone, and this dosing has demonstrated significant survival benefits across multiple prostate cancer settings including metastatic castration-resistant disease (mCRPC) and nonmetastatic CRPC. 1, 2

Recommended Dosing

Standard Dosing:

• 160 mg once daily (four 40 mg capsules or two 80 mg tablets) 1
• Can be taken with or without food 1, 2
• Concurrent prednisone is permitted but not required 2
• Continue until disease progression or unacceptable toxicity

Dose Modifications:

• Reduce to 80 mg daily if coadministered with strong CYP2C8 inhibitors (e.g., gemfibrozil) 1, 3
• No dose adjustment needed for age, race, body weight, or mild-to-moderate renal/hepatic impairment 1
• Severe renal impairment (CrCl <30 mL/min) has not been studied 1

FDA-Approved Indications

Enzalutamide is indicated for:

• Metastatic castration-resistant prostate cancer (mCRPC) - both chemotherapy-naïve and post-docetaxel 2, 4
• Nonmetastatic CRPC with PSA doubling time ≤10 months 2
• Metastatic castration-sensitive prostate cancer (mCSPC) 2

The NCCN designates enzalutamide as a Category 1, preferred treatment option for mCRPC without prior androgen receptor pathway inhibitor (ARPI) therapy 2.

Clinical Efficacy Data

Post-Chemotherapy mCRPC (AFFIRM trial):

• Improved median OS from 13.6 to 18.4 months (HR 0.63, P <0.001) 2
• 54% achieved >50% PSA decline vs 2% with placebo 2
• Quality of life improved with enzalutamide 2

Chemotherapy-Naïve mCRPC (PREVAIL trial):

• Improved median PFS: 20.0 vs 5.4 months 2
• Improved median OS: 35.3 vs 31.3 months 2

Nonmetastatic CRPC (PROSPER trial):

• Metastasis-free survival: 36.6 vs 14.7 months (HR 0.29) 2
• Median OS: 67.0 vs 56.3 months (HR 0.73) 2

Monitoring Parameters

Baseline Assessment:

• Confirm castrate testosterone levels if progression occurs on ADT 2
• Assess seizure risk factors (history of seizures, brain metastases, stroke, brain arteriovenous malformation) 1
• Cardiovascular risk assessment 2
• ECOG performance status 2

Ongoing Monitoring:

• PSA levels regularly
• Testosterone levels to document castrate status 2
• Blood pressure monitoring (hypertension occurs in 12% vs 5% placebo) 2
• Cardiovascular monitoring (major adverse cardiovascular events: 5% vs 3% placebo) 2
• Mental status assessment (mental impairment disorders: 5% vs 2% placebo) 2

Contraindications and Precautions

Key Contraindications:

• History of seizures or predisposing factors - seizure risk is 0.6-0.9% at standard dosing but increases to 1 in 3 patients at doses ≥360 mg daily 2, 1
• Pregnancy (not applicable to this patient population)

Important Drug Interactions: Enzalutamide is a strong CYP3A4 inducer and moderate CYP2C9/CYP2C19 inducer 1, 3:

• Avoid narrow therapeutic index drugs metabolized by these enzymes 3
• Reduces midazolam AUC by 86% 1
• Reduces warfarin (S-warfarin) AUC by 56% 1
• Reduces omeprazole AUC by 72% 1
• Increases digoxin AUC by 33% (P-glycoprotein substrate) 1

Enzalutamide exposure increases with:

• Strong CYP2C8 inhibitors (gemfibrozil): 2.2-fold increase in AUC 1, 3
• Strong CYP3A4 inhibitors (itraconazole): 1.3-fold increase in AUC 1

Adverse Effects Counseling

Most Common Adverse Events (≥10%):

• Fatigue/asthenia (33-34% vs 14-29% placebo) - most common, may warrant dose reduction if severe 2, 5
• Hot flushes (20% vs 10%) 2
• Diarrhea (21% vs 18%) 2
• Headache (12% vs 6%) 2
• Hypertension (12% vs 5%) 2
• Back pain, arthralgia, musculoskeletal pain 6

Serious Adverse Events:

• Seizures (0.6-0.9%) - counsel patients to avoid activities where sudden loss of consciousness could cause serious harm 2, 1
• Major adverse cardiovascular events (5% vs 3%) 2
• Mental impairment disorders (5% vs 2%) 2

Important Counseling Points:

• Severe fatigue may be related to higher drug exposure; if intolerable, dose reduction may help 5
• No QT prolongation at recommended dosing 1
• Cardiac disorders incidence similar to placebo 2
• Most adverse events are mild and manageable 2

Pharmacokinetic Considerations

• Half-life: 5.8 days for enzalutamide; 7.8-8.6 days for active metabolite N-desmethyl enzalutamide 1
• Steady-state: Achieved by Day 28 with 8.3-fold accumulation 1
• Metabolism: Primarily by CYP2C8 (forms active metabolite) and CYP3A4 1
• Protein binding: 97-98% (enzalutamide), 95% (N-desmethyl enzalutamide) 1

Overdose Management

In case of overdose:

• Stop enzalutamide immediately 1
• Initiate general supportive measures 1
• Increased seizure risk - no seizures reported at <240 mg daily, but seizures occurred at 360-600 mg daily 1
• Consider the long half-life (5.8 days) in management 1